caa a22 4500 378853473 CHVBK 20180305123329.0 cr unu---uuuuu 161128e20031204xx s 000 0 eng 10.1515/CCLM.2003.242 doi (NATIONALLICENCE)gruyter-10.1515/CCLM.2003.242 Profiling and in vivo Quantification of Proteins by High Resolution Mass Spectrometry: The Example of Goserelin, an Analogue of Luteinizing Hormone-Releasing Hormone [Elektronische Daten] [Sophie Michalet, Philippe Favreau, Reto Stöcklin] Proteins are essential biomolecules which are frequently involved in major pathological syndromes and are widely used as diagnostic markers or therapeutic agents. The emergence of proteomics will doubtless further increase the significance of proteins both in the clinic and in the life sciences in general. Our main objective is to offer innovative solutions to what we like to call the "post-proteomics era”. To achieve our goal, we intend to develop novel approaches and technologies for in vivo metabolic studies of proteins using mass spectrometry (MS), focusing on pharmacokinetics and pharmacodynamics. Using goserelin as a model, we have successfully developed and validated a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the detection and quantification of an intact analogue of luteinizing hormone-releasing hormone (LHRH) in small volumes of rat plasma samples at concentrations ranging from 0.3 to 405.0 μg/l. To this end, a microbore reversed-phase-HPLC system was coupled on-line to a tandem high resolution quadrupole time-of-flight (Q-TOF) instrument fitted with an electrospray ion source and operated in LC-MS/MS mode. External calibration was used and the high resolution was crucial to discard contaminating signals, which would not have been possible with the more conventional triple quadrupole mass spectrometers operated in a static mode. For low sample amounts, calibration curves were constructed corresponding to rat plasma levels of 0.3 to 16.4 μg/l and found to be of third order with a coefficient of determination greater than 0.999. The relative standard deviation was found to be lower than 15%. A lower limit of detection (LLOD) of 0.17 μg/l and a lower limit of quantification (LLOQ) of 0.3 μg/l were determined. Copyright © 2003 by Walter de Gruyter GmbH & Co. KG Medical equipment & techniques nationallicence Medical diagnosis nationallicence Diseases & disorders nationallicence Michalet Sophie aut Favreau Philippe aut Stöcklin Reto aut Clinical Chemistry and Laboratory Medicine Walter de Gruyter 41/12(2003-12-04), 1589-1598 1434-6621 41:12<1589 2003 41 cclm https://doi.org/10.1515/CCLM.2003.242 text/html Onlinezugriff via DOI 1 research article jats NATIONALLICENCE 856 40 https://doi.org/10.1515/CCLM.2003.242 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Michalet Sophie aut NATIONALLICENCE 700 1- Favreau Philippe aut NATIONALLICENCE 700 1- Stöcklin Reto aut NATIONALLICENCE 773 0- Clinical Chemistry and Laboratory Medicine Walter de Gruyter 41/12(2003-12-04), 1589-1598 1434-6621 41:12<1589 2003 41 cclm CC0 http://creativecommons.org/publicdomain/zero/1.0 nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-gruyter